Log In
Print
BCIQ
Print
Print this Print this
 

ARI-3037MO

  Manage Alerts
Collapse Summary General Information
Company Arisaph Pharmaceuticals Inc.
DescriptionNiacin analog
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationDyslipidemia
Indication DetailsTreat dyslipidemia
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today